Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Amgen (AMGN) Outperforms Industry Year to Date: What's Next?
03:22pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Amgen (AMGN) Outperforms Industry Year to Date: What's Next?
12:47pm, Tuesday, 30'th Aug 2022
Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Why Dividend Stocks Could Soon Be More Attractive -- Thanks to Joe Biden
09:56am, Monday, 29'th Aug 2022 The Motley Fool
A new tax could steer big companies toward paying higher dividends.
Why Dividend Stocks Could Soon Be More Attractive -- Thanks to Joe Biden
05:56am, Monday, 29'th Aug 2022
A new tax could steer big companies toward paying higher dividends.
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocks
10:34am, Sunday, 28'th Aug 2022 MarketWatch
Securities regulators in the two countries came to an agreement on audit protocols, lifting an overhang on Chinese stocks.
Take Advantage Of Low Volatility In Amgen Stock With Options
12:02pm, Thursday, 25'th Aug 2022
Amgen is showing very low implied volatility compared to recent history. That could mean it's a good time to buy an option strangle.
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study
05:33pm, Wednesday, 24'th Aug 2022 Zacks Investment Research
Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study
03:03pm, Wednesday, 24'th Aug 2022
Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.
These 10 stocks matter the most to hedge funds right now
01:45pm, Wednesday, 24'th Aug 2022 MarketWatch
It wasn’t a great start to 2022 for hedge funds, but there’s hope for the second half of this year with this list of stocks that frequent the top 10 holdings of hedge fund portfolios
2 Top Biotech Stocks to Buy for the Long Haul
12:40pm, Wednesday, 24'th Aug 2022 The Motley Fool
Both companies have outperformed the market over the past few decades.
Inflation Reduction Act: VHT Should Be OK, But Amgen Can Fair Better
08:57am, Wednesday, 24'th Aug 2022
The healthcare sector has been under pressure for years as lawmakers have been trying to curb the escalation of pharmaceutical prices. The recent signing of the Inflation Reduction Act marks a major m
2 Top Biotech Stocks to Buy for the Long Haul
08:40am, Wednesday, 24'th Aug 2022
Both companies have outperformed the market over the past few decades.
This Easy-to-Use Stock Strategy Is Crushing the Market
09:44am, Friday, 19'th Aug 2022 The Motley Fool
2022 has been a great year for a popular way to invest.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
12:00pm, Thursday, 18'th Aug 2022 Zacks Investment Research
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
09:02am, Thursday, 18'th Aug 2022
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
